Loading...
•
Mar 31, 2020
Amneal Q1 2020 Earnings Report
Amneal's Q1 2020 financial performance was marked by increased net revenue and net income.
Key Takeaways
Amneal Pharmaceuticals reported a solid operational and financial performance in Q1 2020, with net revenue of $499 million, a 12% increase compared to Q1 2019. GAAP net income was $115 million, and adjusted EBITDA was $134 million, a 20% increase year-over-year. The company is maintaining its full-year 2020 financial outlook.
Net revenue for Q1 2020 was $499 million, a 12% increase compared to Q1 2019.
GAAP net income was $115 million, compared to a net loss of $48 million in the prior year period.
Adjusted EBITDA was $134 million, a 20% increase compared to the prior year period.
The company is maintaining its full-year 2020 financial guidance.
Revenue by Segment
Forward Guidance
Amneal is maintaining its previously provided 2020 guidance; operating cash flow excludes expected $110 million cash tax refund.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...